Mark Rudolph, PhD

Exagen, Inc
Vista, CA, United States

As an R&D scientist at Exagen, I am focused on the development of diagnostic, prognostic, and monitoring solutions for a variety of autoimmune and connective-tissue disorders.

Disclosure information not submitted.

Presentation(s):

• 1221: Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1762: Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time